Materias dentro de su búsqueda.
Materias dentro de su búsqueda.
Historia
24
Películas cinematográficas
16
Música popular
13
Novela estadounidense
12
Jazz
10
Música para órgano
7
Crítica e interpretación
6
Música rock
6
Correspondencia
5
Comedy films
4
Condiciones sociales
4
Diarios íntimos
4
Estados Unidos
4
Música
4
Música vocal (Jazz)
4
Novelistas ingleses
4
Arte
3
Aspectos sociales
3
Bailarines
3
Blues (Música)
3
Christmas music
3
Foreign films
3
Historia y crítica
3
Libros falsos
3
Literatura estadounidense
3
Motetes
3
Música de jazz
3
Operas
3
Songs (High voice) with piano
3
Songs (Medium voice) with piano
3
-
3861por Gedik, Mustafa Emre, Saatci, Ozge, Oberholtzer, Nathaniel, Uner, Meral, Akbulut, Ozge, Cetin, Metin, Aras, Mertkaya, Ibis, Kubra, Caliskan, Burcu, Banoglu, Erden, Wiemann, Stefan, Uner, Aysegul, Aksoy, Sercan, Mehrotra, Shikhar, Sahin, Ozgur“…Finally, TACC3 inhibition elicits ICD in vivo shown by vaccination assay, and it potentiates T-DM1 by inducing dendritic cell (DC) maturation and enhancing infiltration of cytotoxic T cells in the human HER2-overexpressing MMTV.f.huHER2#5 (Fo5) transgenic model. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3862por Laface, Carmelo, Giuliani, Francesco, Melaccio, Assunta, Pappagallo, Maria Nicla, Santoro, Anna Natalizia, Perrone, Martina, De Santis, Pierluigi, Guarini, Chiara, Carrozzo, Daniela, Fedele, Palma“…In recent years, the treatment landscape of patients that are HR+/Her2-negative has changed due to the introduction in clinical practice of new targeted drugs, which have improved patient outcomes. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3863por De Dios-Figueroa, G. Tonantzin, Aguilera-Márquez, Janette del Rocío, García-Uriostegui, Lorena, Hernández-Gutiérrez, Rodolfo, Camacho-Villegas, Tanya A., Lugo-Fabres, Pavel H.“…Epidermal growth factor receptor 2 (HER2) is the second target molecule most commonly used in breast cancer treatment. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3864por Copson, E.R., Abraham, J.E., Braybrooke, J.P., Cameron, D., McIntosh, S.A., Michie, C.O., Okines, A.F.C., Palmieri, C., Raja, F., Roylance, R., Spensley, S.“…BACKGROUND: There is currently no standardised definition for patients at high risk of recurrence of human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (eBC; stages 1–3) after surgery. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3865por Wang, Shengting, Wang, Yufang, Li, Qian, Li, Xiaoming, Feng, Xinghua, Zeng, Kaixuan“…Trastuzumab notably improves the outcome of human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients, however, resistance to trastuzumab remains a major hurdle to clinical treatment. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3866por Wang, Yajie, Liang, Yiran, Ye, Fangzhou, Luo, Dan, Jin, Yuhan, Li, Yaming, Zhao, Wenjing, Chen, Bing, Wang, Lijuan, Yang, Qifeng“…BACKGROUND: Human epidermal growth factor receptor 2‐positive (HER2+) metastatic breast cancer (MBC) is a subtype of breast cancer with a worse prognosis. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3867por Takada, Masahiro, Imoto, Shigeru, Ishida, Takanori, Ito, Yoshinori, Iwata, Hiroji, Masuda, Norikazu, Mukai, Hirofumi, Saji, Shigehira, Ikeda, Takafumi, Haga, Hironori, Saeki, Toshiaki, Aogi, Kenjiro, Sugie, Tomoharu, Ueno, Takayuki, Ohno, Shinji, Ishiguro, Hiroshi, Kanbayashi, Chizuko, Miyamoto, Takeshi, Hagiwara, Yasuhiro, Toi, Masakazu“…PURPOSE: The Phase III POTENT trial demonstrated the efficacy of adding S-1 to adjuvant endocrine therapy for estrogen receptor-positive, HER2-negative early breast cancer. We investigated the efficacy of S-1 across different recurrence risk subgroups. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3868“…In turn, RNF5 inhibition decreases ERK phosphorylation and increases p53 expression through an increase in the EphA2 level in HER2-negative breast cancer cells. Consequently, RNF5 inhibition increases the adhesion and decreases the migration of HER2-negative breast cancer cells, and RNF5 silencing suppresses the growth of xenograft tumors derived from ER-positive, HER2-negative breast cancer cells with increased EphA2 expression and altered phosphorylation. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3869por Pascual, Javier, Gil-Gil, Miguel, Proszek, Paula, Zielinski, Christoph, Reay, Alistair, Ruiz-Borrego, Manuel, Cutts, Rosalind, Ciruelos Gil, Eva M., Feber, Andrew, Muñoz-Mateu, Montserrat, Swift, Claire, Bermejo, Begoña, Herranz, Jesus, Margeli Vila, Mireia, Antón, Antonio, Kahan, Zsuzsanna, Csöszi, Tibor, Liu, Yuan, Fernandez-Garcia, Daniel, Garcia-Murillas, Isaac, Hubank, Michael, Turner, Nicholas C., Martín, Miguel“…CONCLUSIONS: We show impaired survival irrespective of endocrine or chemotherapy-based treatments for patients with hormone receptor–positive/HER2-negative metastatic breast cancer harboring plasma TP53 mutations. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3870por An, Hoyoung, Yang, Hee Won, Oh, Dae Jong, Lim, Eunji, Shin, Jin, Moon, Dong Gyu, Suh, Seung Wan, Byun, Seonjeong, Kim, Tae Hui, Kwak, Kyung Phil, Kim, Bong Jo, Kim, Shin Gyeom, Kim, Jeong Lan, Moon, Seok Woo, Park, Joon Hyuk, Ryu, Seung-Ho, Lee, Dong Woo, Lee, Seok Bum, Lee, Jung Jae, Jhoo, Jin Hyeong, Bae, Jong Bin, Han, Ji Won, Kim, Ki WoongEnlace del recurso
Publicado 2023
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3871por Kaufman, Peter A., Neuberger, Edward, Schwartz, Naomi R. M., Wang, Shu, Liu, Yutong, Hsu, Ling-I, Bartley, Karen, Blahna, Matthew T., Pittner, Brian T., Wong, Gabriel, Anders, Carey“…BACKGROUND: Tucatinib is an oral human epidermal growth factor receptor 2 (HER2)-directed therapy approved in combination with trastuzumab and capecitabine for use in patients with previously treated HER2+ metastatic breast cancer (MBC) with/without brain metastases (BM). …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3872
-
3873por Rediti, Mattia, Fernandez-Martinez, Aranzazu, Venet, David, Rothé, Françoise, Hoadley, Katherine A., Parker, Joel S., Singh, Baljit, Campbell, Jordan D., Ballman, Karla V., Hillman, David W., Winer, Eric P., El-Abed, Sarra, Piccart, Martine, Di Cosimo, Serena, Symmans, William Fraser, Krop, Ian E., Salgado, Roberto, Loi, Sherene, Pusztai, Lajos, Perou, Charles M., Carey, Lisa A., Sotiriou, Christos“…The identification of prognostic markers in patients receiving neoadjuvant therapy is crucial for treatment optimization in HER2-positive breast cancer, with the immune microenvironment being a key factor. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3874“…Poor fixation, inadequate amount of tumor with crushing artefacts and dye application to the biopsy fragments were causes of sample rejection. CONCLUSIONS: Her2/neu amplification was seen in most Her2/neu 3+ cases and approximately one-third of Her2neu 2+ cases. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3875por Qayoom, Sumaira, Agarwal, Apoorva, Agarwal, Preeti, Anand, Akshay, Raj, Rashmi, Gupta, Sameer, Singh, Ajay“…On IHC, no overexpression of HER2Neu was reported in any case, but FISH analysis revealed one point of amplification with HER/centromere enumerator probe (CEP) ratio>2. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3876por Liu, Xinlin, Luan, Linli, Liu, Xi, Jiang, Dingwen, Deng, Junwen, Xu, Jiazhen, Yuan, Yang, Xing, Jiyao, Chen, Bingguan, Xing, Dongming, Huang, Haiming“…While anti-HER2 therapies are approved for the treatment of HER2-positive tumors, a necessity persists for creating novel HER2-targeted agents to resolve therapeutic resistance. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3877“…BACKGROUND: RC48-antibody-drug conjugates (ADC) link humanized anti-HER2 immunoglobulin with monomethyl auristatin E (MMAE). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3878por Wafa, Sanagik Sabry Abu El, El-Ashmawy, Ahmed A., Kassem, Hanaa A. H., Eissa, Ibrahim H., Abu-Elghait, Mohammed, Younis, Nermin A., Younis, Inas Y.“…Pelargonium graveolens L'Hér is an important species of genus Pelargonium with an economic value. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3879por Fakhry, Mariam M., Mattar, Amr A., Alsulaimany, Marwa, Al-Olayan, Ebtesam M., Al-Rashood, Sara T., Abdel-Aziz, Hatem A.“…In addition, enzymatic assays were also run for the most cytotoxic compounds (6a and 6b) toward EGFR and HER2 to demonstrate their dual inhibitory activity. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3880“…INTRODUCTION: Many patients with human epidermal growth factor receptor-2-positive metastatic breast cancer (HER2+ mBC) require subsequent lines of therapy (LOTs) after being treated with pertuzumab and trastuzumab-based regimens in the first line (1L). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto